OXFORD Genome Sciences, of Milton Park, near Abingdon, has changed its name to Oxford BioTherapeutics (OBT).

Chief executive Dr Christian Rohlff said: “The new name truly embodies the core strategic focus of the company on the development of successful antibody-based drugs for cancer, with integrated diagnostics.”

Dr Rohlff added: “I am confident that our integrated approach to the development of antibody therapeutics and diagnostics will enable us to become an important player in the field of personalised medicines in oncology.”

The company rose from the ashes of Oxford University spin-out Oxford Glycosciences, also known as OGS, which disappeared after being taken over by Celltech.